drugset
drugset / Trial / NCT00802425

Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss

NCT00802425 ↗

Phase 2 Completed 210 enrolled Auris Medical AG
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to determine whether AM-111 is effective in the treatment of acute inner ear hearing loss (acute sensorineural hearing loss, ASNHL).

Timeline

Start
2008-12
Primary completion
2012-07
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject BRIMAPITIDE, C-TERMINAL ACID Protein / enzyme biologic — Other

Indications

hearing loss disorder